Genprex Faces Delisting Concerns
Ticker: GNPX · Form: 8-K · Filed: Nov 19, 2024 · CIK: 1595248
Sentiment: bearish
Topics: delisting, compliance, stock-exchange
Related Tickers: GNPX
TL;DR
Genprex might get delisted - stock could tank.
AI Summary
Genprex, Inc. filed an 8-K on November 19, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates potential issues with maintaining its listing on the stock exchange, though specific details regarding the rule or standard were not immediately elaborated upon in this initial report.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to a significant drop in stock value and liquidity if the company cannot rectify the situation.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a major exchange, posing a severe risk to its valuation and operations.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- November 19, 2024 (date) — Filing date
FAQ
What specific listing rule or standard has Genprex, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Genprex, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is November 19, 2024.
What is Genprex, Inc.'s primary business as indicated by its SIC code?
Genprex, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Genprex, Inc. headquartered?
Genprex, Inc. is headquartered in Austin, Texas, with its principal executive offices located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the Commission File Number for Genprex, Inc.?
The Commission File Number for Genprex, Inc. is 001-38244.
Filing Stats: 884 words · 4 min read · ~3 pages · Grade level 14.4 · Accepted 2024-11-19 17:15:37
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
- $1,664,971 — e the Company's stockholders' equity of $1,664,971, as reported in the Company's Quarterly
- $2.5 m — 2024, was below the required minimum of $2.5 million, and because, as of the date of t
- $35 million — value of listed securities of at least $35 million or net income from continuing operation
- $500,000 — et income from continuing operations of $500,000 in the most recently completed fiscal y
Filing Documents
- gnpx20241028_8k.htm (8-K) — 30KB
- 0001437749-24-035757.txt ( ) — 163KB
- gnpx-20241119.xsd (EX-101.SCH) — 3KB
- gnpx-20241119_def.xml (EX-101.DEF) — 12KB
- gnpx-20241119_lab.xml (EX-101.LAB) — 15KB
- gnpx-20241119_pre.xml (EX-101.PRE) — 12KB
- gnpx20241028_8k_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 19, 2024, Genprex, Inc. (the "Company") received a letter (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market ("Nasdaq") notifying the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), because the Company's stockholders' equity of $1,664,971, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, was below the required minimum of $2.5 million, and because, as of the date of the Notice (and as of the date of this report), the Company did not meet either of the alternative compliance standards, relating to market value of listed securities of at least $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. The Notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective, subject to the Company's compliance with the other continued listing requirements, and the Company's regaining compliance with the Stockholders' Equity Requirement. Under Nasdaq rules and as specified in the Notice, the Company has 45 calendar days from November 19, 2024, or until Friday, January 3, 2025 to submit to Nasdaq a plan to regain compliance with the Stockholders' Equity Requirement. If the Company's plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to evidence compliance. The Company is presently evaluating various courses of action to regain compliance and intends to timely submit
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: November 19, 2024 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)